Paclitaxel 化学構造
分子量: 853.91

高品質保証

カスタマーフィードバック(3)

MSDS

製品説明

  • Compare Microtubule Associated Inhibitors
    Microtubule Associated製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 パクリタキセル(タキソール、Onxol、Nov-Onxol)は、人間の内皮細胞の0.1pMのIC50による微小管ポリマー安定剤です。
ターゲット Microtubule (human endothelial cells)
IC50 0.1 pM [1]
In vitro試験 Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
TE-15 M3LVOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLSTZlEUUN3ME2wMlAxODJ6NzFOwG0> MmfLV2FPT0WU
LC-2-ad MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnyPIxKSzVyPUCuNFAxOzF5IN88US=> MkfXV2FPT0WU
RL95-2 M1Pv[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTBwMECwOlY5KM7:TR?= NUfl[ohzW0GQR1XS
MZ1-PC NXizUIJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwMECwO|I6KM7:TR?= Ml2yV2FPT0WU
TE-8 MnTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwMECxNVch|ryP M{\uV3NCVkeHUh?=
SW954 M37iSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\RUmlEPTB;MD6wNFEyQSEQvF2= MmrwV2FPT0WU
TE-11 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjWcXlKSzVyPUCuNFAyOjNizszN NH[0OZRUSU6JRWK=
PSN1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13PVmlEPTB;MD6wNFE{KM7:TR?= NUnUV|hyW0GQR1XS
MOLT-4 Mn3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj5b2ZLUUN3ME2wMlAxOTR7IN88US=> MVLTRW5ITVJ?
697 NXzVZVF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfmOVZKSzVyPUCuNFAyPSEQvF2= M1HyTXNCVkeHUh?=
ETK-1 MnG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Pn[WlEPTB;MD6wNFE2OiEQvF2= M1m3RnNCVkeHUh?=
TE-10 M13RVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzHdmw1UUN3ME2wMlAxOTV2IN88US=> NUn3RYh3W0GQR1XS
HUTU-80 MmXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPRTWM2OD1yLkCwNVY5KM7:TR?= MVnTRW5ITVJ?
NTERA-S-cl-D1 M1vEWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwMECyNFkh|ryP MlfxV2FPT0WU
MFH-ino NIPmWZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTBwMECyOlgh|ryP M2jCVXNCVkeHUh?=
IA-LM NInrd2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEP6OpFKSzVyPUCuNFAzQCEQvF2= MVHTRW5ITVJ?
MC116 NHHH[GlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjZSVRKSzVyPUCuNFAzQDlizszN M{j3VXNCVkeHUh?=
RKO NULIRpNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3vNnFKSzVyPUCuNFAzQThizszN NU\GWGZjW0GQR1XS
MRK-nu-1 NVf5[|BkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjpUWpKSzVyPUCuNFAzQTlizszN M2jwNHNCVkeHUh?=
VA-ES-BJ M1W3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HaV2lEPTB;MD6wNFMh|ryP M{P1UXNCVkeHUh?=
KALS-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTBwMECzNFgh|ryP NUfCNIp3W0GQR1XS
BB30-HNC MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDtTWM2OD1yLkCwN|E1KM7:TR?= MmTCV2FPT0WU
ACN Mn3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnGTlhKSzVyPUCuNFA{OTZizszN NH;hTW9USU6JRWK=
TE-9 NGrDSVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWP0fHZ7UUN3ME2wMlAxOzJ4IN88US=> NV[xZoJZW0GQR1XS
SIG-M5 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rwSWlEPTB;MD6wNFMzPyEQvF2= NVyzRllyW0GQR1XS
no-10 NIK4TINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\GO5NCUUN3ME2wMlAxOzZ{IN88US=> NHr5NmtUSU6JRWK=
EW-1 NGTQXlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTBwMECzO|Eh|ryP NHfx[XFUSU6JRWK=
SK-LMS-1 MkHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXv[W16UUN3ME2wMlAxPDBzIN88US=> MWHTRW5ITVJ?
GT3TKB NF:4cGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwMEC0N|Qh|ryP M4PYZ3NCVkeHUh?=
ES4 NUKzc5psT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWflXo9KUUN3ME2wMlAxPDR7IN88US=> NVqwdFk2W0GQR1XS
IMR-5 MkHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmS0TWM2OD1yLkCwOFUh|ryP M1;GU3NCVkeHUh?=
NCI-H1648 M4\wTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLOeHliUUN3ME2wMlAxPDZ7IN88US=> NFfWfVlUSU6JRWK=
MV-4-11 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17EdWlEPTB;MD6wNFQ4PSEQvF2= NXz3[npIW0GQR1XS
SK-UT-1 NYq3WW1qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLQOIVKSzVyPUCuNFA1QCEQvF2= NXfsToJUW0GQR1XS
NB13 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPtTWM2OD1yLkCwOFkyKM7:TR?= NW\G[2hWW0GQR1XS
DJM-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPjTWM2OD1yLkCwOVMh|ryP NIq5bnJUSU6JRWK=
ES8 M1fDfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33mTGlEPTB;MD6wNFU{QCEQvF2= NG[2dIRUSU6JRWK=
TE-6 Ml7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWL5VXA2UUN3ME2wMlAxPTdizszN M4jUZnNCVkeHUh?=
KS-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnPcFhoUUN3ME2wMlAxPTh{IN88US=> NHy4N|VUSU6JRWK=
TE-1 NH3QXZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\4cmlEPTB;MD6wNFYxPiEQvF2= NIjNOm9USU6JRWK=
ATN-1 NVLuW5FHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHJfIFKSzVyPUCuNFA3ODlizszN NWnuco5jW0GQR1XS
A4-Fuk MkXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWCwd2drUUN3ME2wMlAxPjFzIN88US=> NVm2ZWhjW0GQR1XS
ALL-PO NXfKeXRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHz6XldKSzVyPUCuNFA3OyEQvF2= Mk\aV2FPT0WU
BE-13 MkfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vPWWlEPTB;MD6wNFY{PiEQvF2= NYjVRWRXW0GQR1XS
KM12 MojKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorzTWM2OD1yLkCwOlM4KM7:TR?= M3u4ZXNCVkeHUh?=
NOS-1 M{HyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwMEC2OUDPxE1? NIn3OXhUSU6JRWK=
SW962 NWnZV3BXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFP1NXBKSzVyPUCuNFA3PjJizszN MkLUV2FPT0WU
OCUB-M NETuNVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXsOmZKSzVyPUCuNFA3PjJizszN NFvmRZpUSU6JRWK=
NCI-H510A MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwMEC2OlUh|ryP MnSxV2FPT0WU
EW-16 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPwTWM2OD1yLkCwOlk1KM7:TR?= MlW5V2FPT0WU
KGN MnzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\NVnRKSzVyPUCuNFA4OTJizszN M1XnenNCVkeHUh?=
LS-411N NILUWIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTBwMEC3NVch|ryP M4HTSHNCVkeHUh?=
Becker NHrkZYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwMEC3NkDPxE1? NYWwN2ROW0GQR1XS
HC-1 NUL5fXBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\jfGRKSzVyPUCuNFA4OjFizszN MW\TRW5ITVJ?
CESS NIrneZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;PbHZEUUN3ME2wMlAxPzN5IN88US=> M3LkbXNCVkeHUh?=
KURAMOCHI NV:5ZldLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwMEC3OFgh|ryP NH;5WGdUSU6JRWK=
TGBC24TKB MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1K5emlEPTB;MD6wNFc2OiEQvF2= NIW5XJdUSU6JRWK=
SW982 M3LNR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTBwMEC3OlYh|ryP M1jaW3NCVkeHUh?=
HCE-4 M1\nTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTBwMEC3Olch|ryP MVPTRW5ITVJ?
LOUCY NXX5RlI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfoTWM2OD1yLkCwO|c2KM7:TR?= NF;QUphUSU6JRWK=
8-MG-BA NHvEUpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2r0T2lEPTB;MD6wNFc6PiEQvF2= NXu4TnVnW0GQR1XS
HT-144 NYHDVXk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TM[GlEPTB;MD6wNFgh|ryP MkH6V2FPT0WU
LXF-289 Mn7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\T[m5lUUN3ME2wMlAxQDF6IN88US=> Ml7NV2FPT0WU
RS4-11 NHfmPJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\EVHVUUUN3ME2wMlAxQDN4IN88US=> MV;TRW5ITVJ?
DEL MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7H[25IUUN3ME2wMlAxQDR3IN88US=> M4XJZXNCVkeHUh?=
OCI-AML2 MorYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHGTWM2OD1yLkCwPFUzKM7:TR?= MVfTRW5ITVJ?
CCRF-CEM M{fINGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrQTWM2OD1yLkCwPFcyKM7:TR?= MUHTRW5ITVJ?
A388 MmHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLhUVBKSzVyPUCuNFA5PzRizszN NGfvXZZUSU6JRWK=
KNS-42 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PQXmlEPTB;MD6wNFg6OSEQvF2= M17zZ3NCVkeHUh?=
OVCAR-4 MoDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIC1W4RKSzVyPUCuNFA6ODRizszN NXWzWVRiW0GQR1XS
NCI-H1355 NHLWVVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHz3VXdKSzVyPUCuNFA6OTRizszN M13VO3NCVkeHUh?=
BL-70 Mo\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;ofWlEPTB;MD6wNFk{KM7:TR?= MYPTRW5ITVJ?
BL-41 NIiwXIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTNN3ljUUN3ME2wMlAxQTN2IN88US=> NUXnOHRFW0GQR1XS
A101D NGTYWWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nyT2lEPTB;MD6wNFk3KM7:TR?= MXnTRW5ITVJ?
HL-60 M3Hqd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fSUmlEPTB;MD6wNFk3PiEQvF2= NUexe2hbW0GQR1XS
COR-L279 NFLnXIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInMSI1KSzVyPUCuNFA6QTlizszN NUO0T|Z{W0GQR1XS
NCI-SNU-16 M{nmW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV21U3RvUUN3ME2wMlAyODB6IN88US=> MV\TRW5ITVJ?
Calu-6 NX;selB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHKRWRKSzVyPUCuNFExOTJizszN MXTTRW5ITVJ?
SR NG\sXoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwMEGwNlYh|ryP M{HwWnNCVkeHUh?=
QIMR-WIL NETmXYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwMEGwN|Mh|ryP MX3TRW5ITVJ?
LB647-SCLC NHXO[|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HXeGlEPTB;MD6wNVA2OSEQvF2= MljOV2FPT0WU
RPMI-8226 NUXkcmRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfwXI9KSzVyPUCuNFEyODJizszN M3fn[XNCVkeHUh?=
SK-PN-DW M{jhW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\ocZZKSzVyPUCuNFEyOTJizszN NETJVZRUSU6JRWK=
SF268 M3LFTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIi2cWpKSzVyPUCuNFEyPTFizszN NWjhVGJCW0GQR1XS
HD-MY-Z Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDhdGZRUUN3ME2wMlAyOTZ|IN88US=> MnXzV2FPT0WU
DOHH-2 NG\lVZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwMEGyNFMh|ryP NY\hd2xmW0GQR1XS
SCC-3 Ml;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPJToFKSzVyPUCuNFEzODRizszN NVrpe3Q6W0GQR1XS
ST486 NEW2NXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPtTWM2OD1yLkCxNlA1KM7:TR?= NGT5[3dUSU6JRWK=
NALM-6 M3LGbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfLTWM2OD1yLkCxNlE1KM7:TR?= MWHTRW5ITVJ?
NCI-H1436 M1G1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LaVGlEPTB;MD6wNVI{OSEQvF2= M3LFZXNCVkeHUh?=
KE-37 NEPRZW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGK1do5KSzVyPUCuNFEzOzRizszN M{HXbXNCVkeHUh?=
RPMI-8402 NGjLPYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\sOWVKSzVyPUCuNFEzPTZizszN M1\McXNCVkeHUh?=
RXF393 MlLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzqS4FKSzVyPUCuNFEzPTdizszN M4\0WHNCVkeHUh?=
KARPAS-45 M3\QWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfDeFBXUUN3ME2wMlAyOjdizszN M4GzW3NCVkeHUh?=
HOP-62 MoPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\CSmlEPTB;MD6wNVI4PiEQvF2= MXjTRW5ITVJ?
ES1 NXzq[HNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;0fWlEPTB;MD6wNVI5QCEQvF2= M3:xfHNCVkeHUh?=
L-363 M3fHR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3O4T2lEPTB;MD6wNVM2OSEQvF2= M1XTVHNCVkeHUh?=
GI-1 NVvLXJdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrQTWM2OD1yLkCxN|c{KM7:TR?= NH\admJUSU6JRWK=
CTV-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTBwMEG0O|gh|ryP NX\3XplUW0GQR1XS
TE-5 M3P4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml:xTWM2OD1yLkCxOFk3KM7:TR?= NGXJN21USU6JRWK=
SNU-C2B M3TFW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33NUGlEPTB;MD6wNVQ6PiEQvF2= MUPTRW5ITVJ?
K-562 M1zUbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3H3O2lEPTB;MD6wNVUyPiEQvF2= MYLTRW5ITVJ?
SNB75 MnrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HFSGlEPTB;MD6wNVU1KM7:TR?= M2f1VXNCVkeHUh?=
MOLT-13 M3LRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzr[mFLUUN3ME2wMlAyPjN5IN88US=> NVnnVnJsW0GQR1XS
LS-123 NYfVNHZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7DTWM2OD1yLkCxOlY1KM7:TR?= NVewOY9PW0GQR1XS
NCI-SNU-5 MnPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjoTWM2OD1yLkCxO|AyKM7:TR?= M17LWnNCVkeHUh?=
Daudi MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkiyTWM2OD1yLkCxO|A5KM7:TR?= NXu2RlBFW0GQR1XS
A253 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfITWM2OD1yLkCxO|M5KM7:TR?= NUTFWmlFW0GQR1XS
TGBC1TKB MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVK3dHJDUUN3ME2wMlAyPzV{IN88US=> NUTjXopXW0GQR1XS
SJSA-1 NYjjOYs1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLSTWM2OD1yLkCxO|Y4KM7:TR?= MYLTRW5ITVJ?
NCCIT MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vT[WlEPTB;MD6wNVc3QSEQvF2= M2mxUXNCVkeHUh?=
NCI-H69 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFn4d2RKSzVyPUCuNFE4PzhizszN NWKzS2ZJW0GQR1XS
SH-4 MkHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYi1S3NUUUN3ME2wMlAyQDl3IN88US=> M3ToV3NCVkeHUh?=
HCC1187 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2ToUWlEPTB;MD6wNVkzPCEQvF2= NXmxVnlQW0GQR1XS
HCC1599 NX\rNmczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrLV2FKSzVyPUCuNFIxOiEQvF2= MVHTRW5ITVJ?
ONS-76 M3fvfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjVWHJKSzVyPUCuNFIxOzZizszN NUXYTVlOW0GQR1XS
KU812 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwMEKwN|kh|ryP MkLGV2FPT0WU
ML-2 NV\ZN4VFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwMEKwOFch|ryP M4nsbHNCVkeHUh?=
HCE-T NVzKVWQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnKOIw3UUN3ME2wMlAzODl{IN88US=> MX\TRW5ITVJ?
NCI-H446 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwMEKxNVIh|ryP NGfQfGxUSU6JRWK=
RPMI-6666 MorQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jDc2lEPTB;MD6wNlE1QSEQvF2= Mn7lV2FPT0WU
MOLT-16 NHLsTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TzTmlEPTB;MD6wNlE2OyEQvF2= NH7Qc5JUSU6JRWK=
JiyoyeP-2003 Ml3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLSTZdKSzVyPUCuNFIyPzZizszN MWjTRW5ITVJ?
MHH-PREB-1 NETrVWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTpdXFFUUN3ME2wMlAzOTlzIN88US=> NXXINW5jW0GQR1XS
MC-CAR NIm2XphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;MZWlEPTB;MD6wNlMzPiEQvF2= NF\4c|ZUSU6JRWK=
BC-3 M4LpZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\WTWM2OD1yLkCyN|Q1KM7:TR?= NEnjbnFUSU6JRWK=
KINGS-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPENFJKSzVyPUCuNFI{PTVizszN NEHEbXNUSU6JRWK=
PF-382 NEXQNXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorMTWM2OD1yLkCyN|c5KM7:TR?= NGi2ZpZUSU6JRWK=
J-RT3-T3-5 NHjBZWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHWbGIxUUN3ME2wMlAzOzh|IN88US=> MoDhV2FPT0WU
SF539 NHzDbGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwMEK0NFEh|ryP M1\EZXNCVkeHUh?=
LB831-BLC M3vD[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\WTWM2OD1yLkCyOFg2KM7:TR?= NFi0SIdUSU6JRWK=
DMS-114 NGDW[2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jjdWlEPTB;MD6wNlUxOiEQvF2= M3fpPXNCVkeHUh?=
LB1047-RCC MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwMEK1NUDPxE1? MmC4V2FPT0WU
LB771-HNC M2O1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlq2TWM2OD1yLkCyOVM1KM7:TR?= NYWySnJpW0GQR1XS
BB65-RCC MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzuTWM2OD1yLkCyOVM1KM7:TR?= Ml7UV2FPT0WU
BV-173 M1HZbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DPc2lEPTB;MD6wNlU2PCEQvF2= MneyV2FPT0WU
ARH-77 NFPDb5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{j4OmlEPTB;MD6wNlYxOSEQvF2= NXS2fmtiW0GQR1XS
IST-MEL1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPNcnR1UUN3ME2wMlAzPjJ|IN88US=> NVj4bYh2W0GQR1XS
NB1 NIPxN|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTqTWM2OD1yLkCyOlg4KM7:TR?= MnXCV2FPT0WU
EoL-1-cell NVrn[3JDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGP1O3BKSzVyPUCuNFI3QDhizszN MXfTRW5ITVJ?
KY821 NXXjc4ZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;2UpB5UUN3ME2wMlAzPjl5IN88US=> NHfMeW1USU6JRWK=
CMK MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXBTWM2OD1yLkCyO|M1KM7:TR?= MXTTRW5ITVJ?
NCI-H2126 MmnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnr6TWM2OD1yLkCyO|Y5KM7:TR?= NHPLTIxUSU6JRWK=
NCI-H526 NFfXR4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HLSGlEPTB;MD6wNlg6OSEQvF2= NWLTRmJpW0GQR1XS
COLO-684 MlzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTBwMEK5NFgh|ryP M1z1bHNCVkeHUh?=
NCI-H747 Mn3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;oVGlEPTB;MD6wNlk{OyEQvF2= MlvyV2FPT0WU
JAR MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlf1TWM2OD1yLkCyPVQ3KM7:TR?= M4rmNHNCVkeHUh?=
MEG-01 MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTBwMEK5O|gh|ryP M4PmZXNCVkeHUh?=
MONO-MAC-6 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fYNmlEPTB;MD6wN|AzOyEQvF2= M1HQUnNCVkeHUh?=
IST-SL1 NE\tWnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwMEOwOFIh|ryP MXHTRW5ITVJ?
CPC-N M3HrTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPnTWM2OD1yLkCzNFc6KM7:TR?= NIHYbYRUSU6JRWK=
NCI-H1963 NGTZWI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfpO25KSzVyPUCuNFMyOzFizszN NYLlbGtIW0GQR1XS
K052 NX3oNFUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4n0eGlEPTB;MD6wN|I1PyEQvF2= M{nhdnNCVkeHUh?=
KM-H2 M2HLOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnjVYNoUUN3ME2wMlA{OzB5IN88US=> M13aO3NCVkeHUh?=
TE-12 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHmOol2UUN3ME2wMlA{OzB7IN88US=> MVnTRW5ITVJ?
TK10 M1rtSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfGTWM2OD1yLkCzN|U3KM7:TR?= MnvUV2FPT0WU
NMC-G1 M4DiNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwMEO0OVIh|ryP NHvUd4ZUSU6JRWK=
no-11 MlXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjvT|hsUUN3ME2wMlA{PDd6IN88US=> NVK3fJZjW0GQR1XS
NCI-H524 NEC0T4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HkUmlEPTB;MD6wN|UzQSEQvF2= NVnBdodYW0GQR1XS
MHH-CALL-2 NUWzOo1rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrKVVhKSzVyPUCuNFM2PjJizszN NXqwOXZmW0GQR1XS
GB-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknOTWM2OD1yLkCzOkDPxE1? M{Htc3NCVkeHUh?=
OPM-2 Mni3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLobGdjUUN3ME2wMlA{Pjd|IN88US=> MWDTRW5ITVJ?
RH-1 NGXNbI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTkUHBuUUN3ME2wMlA{QDF7IN88US=> MorXV2FPT0WU
NCI-H64 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3m4U2lEPTB;MD6wN|g2PyEQvF2= NYDTOpp5W0GQR1XS
EVSA-T MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFS1[ohKSzVyPUCuNFM6OjNizszN NUPrSXUyW0GQR1XS
KARPAS-299 NXjmeZBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPpOFdKSzVyPUCuNFM6QCEQvF2= M33qUnNCVkeHUh?=
MZ7-mel NWix[ZFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1exU2lEPTB;MD6wOFA1KM7:TR?= NEDnbJhUSU6JRWK=
LB373-MEL-D MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DNdWlEPTB;MD6wOFExPSEQvF2= NXi4W5NvW0GQR1XS
HEL MoK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XMWmlEPTB;MD6wOFE1KM7:TR?= MWHTRW5ITVJ?
SW872 MlXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;KNpFKSzVyPUCuNFQzOSEQvF2= Ml3WV2FPT0WU
DU-4475 M33XVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Hs[GlEPTB;MD6wOFI1PCEQvF2= M3rRNHNCVkeHUh?=
IST-SL2 NXPXbmRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGm2[2FKSzVyPUCuNFQzPzVizszN M1WyXHNCVkeHUh?=
NCI-H82 M4fnOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwMESzNFch|ryP NFf6Z4tUSU6JRWK=
LC4-1 Ml;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPtepVKSzVyPUCuNFQ{PTFizszN MVXTRW5ITVJ?
HDLM-2 NYqyN3FRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvXTWM2OD1yLkC0N|kzKM7:TR?= NV\vd|dwW0GQR1XS
MMAC-SF MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXX[YxKSzVyPUCuNFQ2OzRizszN NFr2[VZUSU6JRWK=
L-540 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjQNmpYUUN3ME2wMlA1PjN7IN88US=> NGnVUXBUSU6JRWK=
MZ2-MEL NV\yS3VUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jvUGlEPTB;MD6wOFc1OiEQvF2= M{G2c3NCVkeHUh?=
LU-134-A MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDzTWM2OD1yLkC0O|c{KM7:TR?= MUnTRW5ITVJ?
UACC-257 NV3MZWQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3y2NWlEPTB;MD6wOFg1QSEQvF2= NGfSdohUSU6JRWK=
NCI-H1581 NV[wV2FVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwMES5OVMh|ryP MVPTRW5ITVJ?
NB17 NVO2NmZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrONWhKSzVyPUCuNFQ6PzlizszN NEf2SVdUSU6JRWK=
SBC-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXafXlvUUN3ME2wMlA2ODR{IN88US=> NVe5TYd[W0GQR1XS
TALL-1 NEjKfnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml22TWM2OD1yLkC1NFQ2KM7:TR?= NYP6[WlpW0GQR1XS
NCI-H1304 M{TuZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVz2fXFjUUN3ME2wMlA2OjB6IN88US=> MoXkV2FPT0WU
NEC8 MnrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzvWVFHUUN3ME2wMlA2Ojh4IN88US=> NX\Vcmd5W0GQR1XS
CAL-148 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTBwMEW0N|kh|ryP Mm\MV2FPT0WU
CGTH-W-1 NXK5[IE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3G1fGlEPTB;MD6wOVQ1QSEQvF2= MULTRW5ITVJ?
NCI-H889 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwMEW1PVIh|ryP MlT2V2FPT0WU
GR-ST M2frSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rGWmlEPTB;MD6wOVYzOSEQvF2= M4\Rd3NCVkeHUh?=
KARPAS-422 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPoTWM2OD1yLkC1OlUh|ryP NF[zUYxUSU6JRWK=
RPMI-8866 NITWUpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwMEW3NVIh|ryP MVrTRW5ITVJ?
SCLC-21H MkjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwMEW4PFQh|ryP MmrwV2FPT0WU
COR-L88 MljxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M12yfGlEPTB;MD6wOVkzPyEQvF2= NHKyOWZUSU6JRWK=
LU-139 MoXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fCRmlEPTB;MD6wOVk5PiEQvF2= MleyV2FPT0WU
SF126 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmC0TWM2OD1yLkC2NVM{KM7:TR?= NILlUXlUSU6JRWK=
NCI-H1882 M2ntRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3X2[WlEPTB;MD6wOlQzPCEQvF2= NHnHUYFUSU6JRWK=
EW-24 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHRTWM2OD1yLkC2OFg{KM7:TR?= MUfTRW5ITVJ?
CP67-MEL MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIP0UWVKSzVyPUCuNFY5OSEQvF2= MVvTRW5ITVJ?
DG-75 MlnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnjZopKSzVyPUCuNFY5QTlizszN NH;OSlJUSU6JRWK=
LOXIMVI MlPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTBwMEewNlgh|ryP NE[wNoVUSU6JRWK=
HH NIHvN4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHMTWM2OD1yLkC3NVU4KM7:TR?= MV7TRW5ITVJ?
K5 Ml\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HTT2lEPTB;MD6wO|IzPiEQvF2= M2Do[HNCVkeHUh?=
EC-GI-10 MkHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjMXGZKSzVyPUCuNFczPTdizszN Ml\sV2FPT0WU
SK-N-DZ NUjKcYdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjmTVZKSzVyPUCuNFc{ODdizszN Mlj3V2FPT0WU
A3-KAW NIjiN2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXMTWM2OD1yLkC3N|UyKM7:TR?= MmPhV2FPT0WU
MLMA NYrDfllHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3kO5pPUUN3ME2wMlA4PDZ3IN88US=> NEHjNW9USU6JRWK=
LB996-RCC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzSWnhEUUN3ME2wMlA4PzB5IN88US=> MWrTRW5ITVJ?
OS-RC-2 MoX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYX1W2VrUUN3ME2wMlA4PzR6IN88US=> NFL3d5RUSU6JRWK=
CTB-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TocGlEPTB;MD6wO|gyKM7:TR?= MUnTRW5ITVJ?
IST-MES1 M3vTeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwMEe5NVIh|ryP NXLBZmd5W0GQR1XS
LS-1034 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LKcmlEPTB;MD6wPFA{PSEQvF2= NXXq[ZI3W0GQR1XS
HT NFnw[|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MneyTWM2OD1yLkC4NFg3KM7:TR?= MUHTRW5ITVJ?
NCI-H2141 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\y[IxKSzVyPUCuNFgyKM7:TR?= M4i0eHNCVkeHUh?=
LB2518-MEL MmnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rqXGlEPTB;MD6wPFE1OSEQvF2= NYTFbY1jW0GQR1XS
GI-ME-N NHHK[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXITWM2OD1yLkC4OFUzKM7:TR?= M2[0fHNCVkeHUh?=
TGW NYrTem4yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mni5TWM2OD1yLkC4OlA4KM7:TR?= NF3oR4VUSU6JRWK=
SK-NEP-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\Lb2lEPTB;MD6wPFY1OSEQvF2= NHvQd3VUSU6JRWK=
NOMO-1 MlrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTBd4R3UUN3ME2wMlA6Ojd3IN88US=> NEf0W3lUSU6JRWK=
ES6 M{PTb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fZOGlEPTB;MD6wPVU5QSEQvF2= NF;BNmJUSU6JRWK=
NCI-H209 M37XNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7ab5JEUUN3ME2wMlA6Pzh4IN88US=> MYfTRW5ITVJ?
GAK MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwMUCxOkDPxE1? NEfDWo5USU6JRWK=
BC-1 NVKz[YRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;KTWM2OD1yLkGwN|YyKM7:TR?= NUL2Znl5W0GQR1XS
KLE MkXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4G2TWlEPTB;MD6xNFQ1OyEQvF2= MYDTRW5ITVJ?
EW-3 NEizboNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPHXVNKSzVyPUCuNVA6QCEQvF2= NEXEe4VUSU6JRWK=
NKM-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\neI5KSzVyPUCuNVEyKM7:TR?= MmPhV2FPT0WU
D-336MG NGfvdnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPNbWRuUUN3ME2wMlEyOjR2IN88US=> NGrO[WhUSU6JRWK=
NB69 NIjve4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvGWm9KSzVyPUCuNVE{ODFizszN NYXIe21VW0GQR1XS
D-263MG NWPvS2trT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoW4TWM2OD1yLkGxO|EzKM7:TR?= NVfyXo1[W0GQR1XS
KP-N-YS MkGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTBwMUKyPVEh|ryP MmnEV2FPT0WU
NCI-H1155 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXaTWM2OD1yLkGyOVU5KM7:TR?= Ml\mV2FPT0WU
BOKU MnrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPYRnVwUUN3ME2wMlEzPTd7IN88US=> NWHR[IU5W0GQR1XS
LAMA-84 M3;Te2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\KdGlEPTB;MD6xNlk6KM7:TR?= NYDrOWFzW0GQR1XS
Raji MoX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnMUIxKSzVyPUCuNVMyOTdizszN Mk\6V2FPT0WU
LU-65 NGKzbWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwMUOzNFch|ryP M2fZNHNCVkeHUh?=
NCI-H187 NXXn[IFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTYfYdQUUN3ME2wMlE{QTJ2IN88US=> M1W2NHNCVkeHUh?=
GCIY NUDWfVJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwMUS5NFEh|ryP M3PQXnNCVkeHUh?=
NCI-H2107 NHP2cGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTBwMUWwPEDPxE1? M1XRU3NCVkeHUh?=
NCI-H1522 NYrvSY1RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwMUWyOlYh|ryP MYjTRW5ITVJ?
NB6 NGrIZotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzPbFdRUUN3ME2wMlE2PjJ|IN88US=> Mn[5V2FPT0WU
EM-2 MkThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTBwMUW3NFYh|ryP NXvkdYhnW0GQR1XS
HCC2218 M1;Sdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTqN3J2UUN3ME2wMlE2QThizszN MVvTRW5ITVJ?
NCI-H748 MkfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjLV5RSUUN3ME2wMlE3Ozd4IN88US=> M4\jeHNCVkeHUh?=
MS-1 NFrlc3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjBZlc{UUN3ME2wMlE3PTN5IN88US=> NWnHOJprW0GQR1XS
NB5 MmPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTBwMU[1PVch|ryP NUXDbGc2W0GQR1XS
OMC-1 Mk\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XibmlEPTB;MD6xOlY5QCEQvF2= MWfTRW5ITVJ?
NCI-H345 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Xrd2lEPTB;MD6xOlkzQCEQvF2= Ml7JV2FPT0WU
L-428 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[yU5pwUUN3ME2wMlE3QTR3IN88US=> M4rRcHNCVkeHUh?=
SCH MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrvZ2ZCUUN3ME2wMlE5Pjh3IN88US=> MkPYV2FPT0WU
NCI-H1417 M4j4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPlbZk1UUN3ME2wMlE6OjJ5IN88US=> MUPTRW5ITVJ?
COLO-320-HSR MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PMO2lEPTB;MD6xPVU{OiEQvF2= MYrTRW5ITVJ?
BT-474 NUXFOIE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHSOVVKSzVyPUCuNlA5QTJizszN MmrwV2FPT0WU
GDM-1 NHi0eHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknPTWM2OD1yLkKxPVcyKM7:TR?= M17IPHNCVkeHUh?=
NCI-H2196 NWC3VYU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3u4U2lEPTB;MD6yNlI{PSEQvF2= NWKzTWVEW0GQR1XS
KP-N-RT-BM-1 NU\sSWhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofSTWM2OD1yLkKyN|Q6KM7:TR?= M2q5[HNCVkeHUh?=
KNS-81-FD NHi1O3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\FeGlEPTB;MD6yNlk2QCEQvF2= NYCyVmV5W0GQR1XS
COLO-668 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HkWGlEPTB;MD6yN|Y4PSEQvF2= M1\3WnNCVkeHUh?=
C2BBe1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn23TWM2OD1yLkK2O|Q4KM7:TR?= NXTobog2W0GQR1XS
Ramos-2G6-4C10 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3y4fmlEPTB;MD6yOlk2PCEQvF2= NEHhfWNUSU6JRWK=
CAS-1 MnXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXezNGh1UUN3ME2wMlI4ODl4IN88US=> NHnQ[W5USU6JRWK=
GOTO NFLUeGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXobYhbUUN3ME2wMlI4QDl2IN88US=> MYnTRW5ITVJ?
LP-1 NGS1XW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYflV4VYUUN3ME2wMlI5ODV5IN88US=> M1mzbHNCVkeHUh?=
NCI-SNU-1 NULZTYN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrOTHE2UUN3ME2wMlI6PDJ{IN88US=> MlnzV2FPT0WU
EB-3 MoLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\1fGlEPTB;MD6yPVk4QSEQvF2= M3nmNHNCVkeHUh?=
MHH-NB-11 M3ftRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jvfmlEPTB;MD6zNFQxOiEQvF2= NXX0U5ozW0GQR1XS
SK-N-FI NITVUW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[2ZmxKSzVyPUCuN|E3QTJizszN MYrTRW5ITVJ?
HCC2157 M2ThO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LafmlEPTB;MD6zN|kyOyEQvF2= MXrTRW5ITVJ?
SIMA NXfWUpNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnWzTWM2OD1yLkO0OVgyKM7:TR?= MkH4V2FPT0WU
MDA-MB-134-VI MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTBwM{[5Nlgh|ryP M1Tue3NCVkeHUh?=
NCI-H1694 M3THSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHuxXZJKSzVyPUCuN|ch|ryP MnqxV2FPT0WU
EHEB M{nvPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoH1TWM2OD1yLkO5NFg2KM7:TR?= MnfMV2FPT0WU
U-266 NHS1dJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzGTWM2OD1yLkO5PFQ3KM7:TR?= NIrCVFdUSU6JRWK=
LC-1F MlzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLCN3g4UUN3ME2wMlQ{PzZ3IN88US=> M2ryXHNCVkeHUh?=
SHP-77 NFTBXIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPvTWM2OD1yLkS3PFU2KM7:TR?= MUXTRW5ITVJ?
LS-513 M1PzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M36zWWlEPTB;MD60PVMxPyEQvF2= M3L0ZnNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo試験 The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]
臨床試験 Paclitaxel has entered in a Phase III clinical trial for the treatment of tubular breast cancer stage II, mucinous breast cancer stage II, breast cancer female NOS and invasive ductal breast cancer.
特集

プロトコル (参考用のみ)

細胞アッセイ: [1]

細胞株 Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
濃度 0.1-100 pM
反応時間 72 hours
実験の流れ Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.

動物実験: [4]

動物モデル Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
製剤 Control
投薬量 20 mg/kg
投与方法 Administered via i.v.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Paclitaxel SDF
分子量 853.91
化学式

C47H51NO14

CAS No. 33069-62-4
保管 3年-20℃
2年-80℃in solvent
別名 NSC 125973
溶解度 (25°C) * In vitro DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water <1 mg/mL
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80 30mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)-

文献中の引用 (16)

Frequently Asked Questions

  • Question 1
    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

    Answer: Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related 微小管関連 阻害剤

  • TAI-1

    TAI-1 is a potent and specific Hec1 inhibitor, which disrupts Hec1-Nek2 protein interaction.

  • Docetaxel Trihydrate

    Docetaxel, an analog of taxol, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.

  • Combretastatin A4

    Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.

  • FRAX597

    FRAX597 is a potent, ATP-competitive inhibitor of group I PAKs with IC50 of 8 nM, 13 nM, and 19 nM for PAK1, PAK2, and PAK3, respectively.

  • Docetaxel

    Docetaxel is an microtubule disassembly inhibitor with IC50 of a range of 0.31-100 ηM.

  • Vincristine

    Vincristine is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM.

  • Nocodazole

    Nocodazoleは反微小管薬品で、 ABL、 ABL(E255K) 、ABL(T315I)に作用すると 、 IC50 が それぞれ0.21 μM、 0.53 μM 、 0.64 μMになる。

  • Vinblastine

    Vinblastine inhibits microtubule formation and supresses nAChR activity with IC50 of 8.9 μM.

  • Vinorelbine Tartrate

    Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.

最近チェックしたアイテム

Tags: Paclitaxelを買う | Paclitaxel供給者 | Paclitaxelを購入する | Paclitaxel費用 | Paclitaxel生産者 | オーダーPaclitaxel | Paclitaxel代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ